Baillie Gifford & CO Coherus Bio Sciences, Inc. Transaction History

Baillie Gifford & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	BUY	$7.17 - $13.87 $1,104 - $2,135	154 Added 10.76%	1,585 $15,000
Q4 2021 Jan 20, 2022	SELL	$15.81 - $18.99 $2,750 - $3,304	-174 Reduced 10.84%	1,431 $23,000
Q3 2021 Oct 19, 2021	SELL	$12.68 - $17.79 $2,561 - $3,593	-202 Reduced 11.18%	1,605 $26,000
Q1 2021 May 06, 2021	BUY	$14.42 - $21.39 $1,499 - $2,224	104 Added 6.11%	1,807 $26,000
Q4 2020 Feb 10, 2021	BUY	$16.56 - $18.94 $28,201 - $32,254	1,703 New	1,703 $30,000

143

82.7M

79.1K

100K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $80.8M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.